Serotonin 5-HT 2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents
Expert Opinion on Drug Safety August 15, 2023 DOI: 10.1080/14740338.2023.2248883
Summary
The therapeutic promise of Psilocybin and Lysergic acid diethylamide (LSD) as Medicine is significant. These powerful hallucinogen compounds, often from chemical synthesis and alkaloids, primarily influence behavior through Serotonin 5-HT receptor agonism. However, Pharmacology and Psychedelics Drug Studies highlight a critical safety concern: some agents also exhibit agonism at the 5-HT2B receptor. This Neurotransmitter Receptor Influence on Behavior is linked to valvular heart disease. Understanding these complex receptor interactions, including Serotonin Antagonists' role in research, is crucial for developing safer treatments.
Abstract
KEYWORDS: PsilocybinLysergic acid diethylamide (LSD)ecstasyvalvular heart disease5HT2B receptor agonismFDA guidance